Knowledge Application Program

KAP Keys

For Clinicians

Based on TIP 45
Detoxification and Substance Abuse Treatment

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment
www.samhsa.gov
Introduction

KAP Keys were developed to accompany the Treatment Improvement Protocol (TIP) Series published by the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA). These KAP Keys are based entirely on TIP 45 and are designed to meet the needs of the busy clinician for concise, easily accessed “how-to” information.

Other Treatment Improvement Protocols (TIPs) that are relevant to these KAP Keys:

**TIP 33:** Treatment for Stimulant Use Disorders  **BKD289**

**TIP 35:** Enhancing Motivation for Change in Substance Abuse Treatment  **BKD342**

**TIP 40:** Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction  **BKD500**

**TIP 43:** Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs  **BKD524**
1

Symptoms and Signs of Conditions That Require Immediate Medical Attention
KAP KEYS Based on TIP 45
Detoxification and Substance Abuse Treatment

• Change in mental status
• Increasing anxiety and panic
• Hallucinations
• Seizures
• Insomnia
• Changes in responsiveness of pupils
• Significant increases and/or decreases in blood pressure and heart rate
• Abdominal pain
• Upper and lower gastrointestinal bleeding
• Temperature greater than 100.4 °F (these patients should be considered potentially infectious)
• Heightened deep tendon reflexes and ankle clonus, a reflex beating of the foot when pressed rostrally (i.e., toward the mouth of the patient), indicating profound central nervous system irritability and the potential for seizures
Fast Facts:

- Cocaine and amphetamines (such as methamphetamine) are the most frequently abused central nervous system stimulants.
- Stimulants are intensely rewarding and are actually self-administered by laboratory animals to the point of death.

Symptoms of Cocaine and Other Stimulant Intoxication

- Dilated pupils
- Profuse sweating, often with chills
- Elevated blood pressure
- Elevated temperature
- Increased heartbeat
- Slowed heart action
- Teeth grinding
- Tremors
- Seizures—mostly for cocaine users

Withdrawal Symptoms of Cocaine and Other Stimulants

- Depression
- Hypersomnia or insomnia
- Fatigue
- Anxiety
- Psychomotor retardation (slow reflexes)
- Paranoia
- Drug craving

Management of Withdrawal From Cocaine, Methamphetamine, and Other Stimulants

- No medication has been developed for treating stimulant withdrawal.
- The most effective means of treating stimulant withdrawal involves establishing a period of abstinence from these agents.
- Stimulant withdrawal is not usually associated with medical complications.
- Amantadine may help reduce cocaine use in patients with more severe withdrawal symptoms.
- Modafinil, an anti-narcolepsy agent with stimulant-like action, is currently under investigation by one research group as a cocaine detoxification agent.
- Antidepressants, such as selective serotonin reuptake inhibitors, can be prescribed for the depression that often accompanies methamphetamine or other amphetamine withdrawal.
Fast Facts:

• The clinical presentation of intoxication from alcohol varies widely depending in part on blood alcohol level and level of previously developed tolerance.
• Since the elimination rate of alcohol from the body generally is 10mg to 30mg percent per hour, the goals for the treatment of alcohol intoxication are to preserve respiration and cardiovascular function until alcohol levels fall into a safe range.

### Symptoms of alcohol intoxication

<table>
<thead>
<tr>
<th>Blood alcohol level</th>
<th>Symptoms</th>
</tr>
</thead>
</table>
| 20mg-100mg percent | • Mood and behavioral changes  
• Reduced coordination  
• Impairment of ability to drive a car or operate machinery |
| 101mg-200mg percent | • Reduced coordination of most activities  
• Speech impairment  
• Trouble walking  
• General impairment of thinking/judgment |
| 201mg-300mg percent | • Marked impairment of thinking, memory, and coordination  
• Marked reduction in level of alertness  
• Memory blackouts  
• Nausea and vomiting |
| 301mg-400mg percent | • Worsening of above symptoms with reduction of body temperature and blood pressure  
• Excessive sleepiness  
• Amnesia  
• Nausea and vomiting |
| 401mg-800mg percent | • Difficulty waking the patient (coma)  
• Serious decreases in pulse, temperature, blood pressure, and rate of breathing  
• Urinary and bowel incontinence  
• Death |

Continued on back
**Alcohol Withdrawal Symptoms**
- Restlessness, irritability, anxiety, agitation
- Anorexia, nausea, vomiting
- Hallucinations (auditory, visual, or tactile)
- Insomnia, intense dreaming, nightmares
- Grand mal seizures
- Hyperthermia
- Increased sensitivity to sound, light, and tactile sensations
- Delusions, usually of paranoid or persecutory varieties
- Tremor, elevated heart rate, increased blood pressure
- Poor concentration, impaired memory and judgment
- Delirium/disorientation with regard to time, place, person, and situation; fluctuation in level of consciousness

**Management of Withdrawal From Alcohol**
- The course of alcohol withdrawal is unpredictable; it is hard to tell who will or will not experience life-threatening complications.
- Deciding whether or not to use medical management for alcohol withdrawal requires that patients be separated into three groups:
  1. Clients who have a history of the most extreme forms of withdrawal, that of seizures and/or delirium. The medication treatment of this group should proceed as quickly as possible.
  2. Patients who are already in withdrawal and demonstrating moderate symptoms of withdrawal also require immediate medication.
  3. The third group includes patients who may still be intoxicated, or who have, at the time of admission, been abstinent for only a few hours and have not developed signs or symptoms of withdrawal. A decision regarding medication treatment for this group should be based on advancing age, number of years with alcohol dependence, and the number of previously treated or untreated severe withdrawals.

- The major goal of medical detoxification is to avoid seizures and a special state of delirium called delirium tremens (DTs) with aggressive use of the primary detoxification drug.
- Several medications used in the treatment of alcohol withdrawal are: benzodiazepine, barbiturates, anticonvulsants, beta blockers/alpha adrenergic agonists, antipsychotics, relapse prevention agents.
Fast Facts:
- Opioids are highly addicting.
- Chronic use of opioids leads to withdrawal symptoms that, although not medically dangerous, can be highly unpleasant and produce intense discomfort.

**Signs and Symptoms of Opioid Intoxication**

**Opioid Intoxication Signs**
- Slow pulse
- Low body temperature
- Pinpoint pupils
- Slurred speech
- Low blood pressure
- Sedation
- Slowed movement
- Head nodding

**Opioid Intoxication Symptoms**
- Euphoria
- Pain-killing effects
- Calmness

**Signs and Symptoms of Opioid Withdrawal**

**Opioid Withdrawal Signs**
- Fast pulse
- High body temperature
- Enlarged pupils
- Sweating
- Increased respiratory rate
- Yawning
- High blood pressure
- Insomnia
- Abnormally heightened reflexes
- Gooseflesh
- Tearing (as in crying)
- Runny nose

**Opioid Withdrawal Symptoms**
- Abdominal cramps
- Vomiting
- Nausea
- Diarrhea
- Anxiety
- Bone and muscle pain

Continued on back
Management of Withdrawal From Heroin and Other Opioids

- It is not recommended that clinicians attempt to manage significant opioid withdrawal symptoms without effective detoxification agents.
- The management of opioid withdrawal with medication is most commonly achieved through the use of methadone.
- The initial dose requirements for methadone are determined by estimating the amount of opioid use and gauging the patient’s response to administered methadone.
- Methadone can be given once daily and generally tapered over 3 to 5 days in 5 to 10mg daily reductions.
- Clonidine can also be used to treat opioid withdrawal, but it is usually ineffective for common symptoms such as insomnia, muscle aches, and drug craving.
Fast Facts:
• Marijuana and hashish are the two substances containing THC (delta-9-tetrahydrocannabinol) commonly used today.
• The THC abstinence syndrome usually starts within 24 hours of cessation. The amount of THC that one needs to ingest in order to experience withdrawal is unknown. It can be assumed, however, that heavier consumption is more likely to be associated with withdrawal symptoms.

Symptoms of Cannabis Intoxication
• Impaired short-term memory
• Impaired attention, judgment, and other cognitive functions
• Impaired coordination and balance
• Increased heart rate

Cannabis Withdrawal Symptoms
• Anxiety
• Restlessness
• Irritability
• Sleep disturbance
• Change in appetite
• Tremor
• Sweating
• Elevated heart rate
• Nausea, vomiting, diarrhea

Management of Withdrawal From Cannabis
• There are no medical complications of withdrawal from THC, and medication is generally not required to manage withdrawal.
• Screening the patient for suicidal ideation or other mental health problems is warranted.
• The patient should be encouraged to maintain abstinence from THC as well as other addictive substances.
Nicotine
Two issues regarding tobacco smoking merit consideration by staff of substance abuse detoxification programs. The first is the program management’s desire to establish a smoke-free treatment environment to comply with workplace ordinances and to safeguard the health and comfort of patients from exposure to second hand smoke. The second issue is the patient’s dependence on nicotine as a drug of abuse.

Drugs That Do Not Produce a Withdrawal Syndrome
Chronic use of PCP can cause toxic psychosis that takes days or weeks to clear; however, PCP does not have a withdrawal system. LSD and ecstasy do not produce physical dependence.

Polydrug Use
People who abuse substances rarely use just one substance. Typical combinations and preferred modes of treatment are as follows:
• Alcohol and stimulant: Treat alcohol abuse.
• Cocaine and opiate: Treat opiate dependence.
• Cocaine and amphetamine: No detoxification protocol is known.
### Initial Evaluation Domains

**KAP KEYS Based on TIP 45**

*Detoxification and Substance Abuse Treatment*

<table>
<thead>
<tr>
<th><strong>Biomedical</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Health History</strong></td>
</tr>
<tr>
<td><strong>Mental Status</strong></td>
</tr>
<tr>
<td><strong>General Physical Assessment With Neurological Exam</strong></td>
</tr>
<tr>
<td><strong>Temperature, Pulse, Blood Pressure</strong></td>
</tr>
<tr>
<td><strong>Patterns of Substance Abuse</strong></td>
</tr>
<tr>
<td><strong>Urine Toxicology Screen</strong></td>
</tr>
<tr>
<td><strong>Past Substance Abuse Treatments or Detoxification</strong></td>
</tr>
</tbody>
</table>

*Continued on back*
<table>
<thead>
<tr>
<th>Psychosocial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic Features</strong></td>
</tr>
<tr>
<td>Gather information on gender, age, ethnicity, culture, language, and educational level.</td>
</tr>
<tr>
<td><strong>Living Conditions</strong></td>
</tr>
<tr>
<td>Is the patient homeless or living in a shelter? What is the living situation? Are significant others in the home (and, if so, can they safely supervise)?</td>
</tr>
<tr>
<td><strong>Violence, Suicide Risk</strong></td>
</tr>
<tr>
<td>Is the patient aggressive, depressed, or hopeless? Is there a history of violence?</td>
</tr>
<tr>
<td><strong>Transportation</strong></td>
</tr>
<tr>
<td>Does the patient have adequate means to get to appointments? Do other arrangements need to be made?</td>
</tr>
<tr>
<td><strong>Financial Situation</strong></td>
</tr>
<tr>
<td>Is the patient able to purchase medications and food? Does the patient have adequate employment and income?</td>
</tr>
<tr>
<td><strong>Dependent Children</strong></td>
</tr>
<tr>
<td>Is the patient able to care for children, provide adequate child care, and ensure the safety of children?</td>
</tr>
<tr>
<td><strong>Legal Status</strong></td>
</tr>
<tr>
<td>Is the patient a legal resident? Are there pending legal matters? Is treatment court ordered?</td>
</tr>
<tr>
<td><strong>Physical, Sensory, or Cognitive Disabilities</strong></td>
</tr>
<tr>
<td>Does the client have disabilities that require consideration?</td>
</tr>
</tbody>
</table>
### Recommended Areas for Assessment to Determine Appropriate Rehabilitation Plans

**KAP KEYS Based on TIP 45**

**Detoxification and Substance Abuse Treatment**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Conditions and Complications</td>
<td>Infectious illnesses, chronic illnesses requiring intensive or specialized treatment, pregnancy, and chronic pain</td>
</tr>
<tr>
<td>Motivation/Readiness to Change</td>
<td>Degree to which the client acknowledges that substance use behaviors are a problem and is willing to confront them honestly</td>
</tr>
<tr>
<td>Physical, Sensory, or Mobility Limitations</td>
<td>Physical conditions that may require specially designed facilities or staffing</td>
</tr>
<tr>
<td>Relapse History and Potential</td>
<td>Historical relapse patterns, periods of abstinence, and predictors of abstinence; client awareness of relapse triggers and craving</td>
</tr>
<tr>
<td>Substance Abuse/Dependence</td>
<td>Frequency, amount, and duration of use; chronicity of problems; indicators of abuse or dependence</td>
</tr>
<tr>
<td>Developmental and Cognitive Issues</td>
<td>Ability to participate in confrontational treatment settings, and benefit from cognitive interventions and group therapy</td>
</tr>
<tr>
<td>Family and Social Support</td>
<td>Degree of support from family and significant others, substance-free friends, involvement in support groups</td>
</tr>
<tr>
<td>Co-Occurring Psychiatric Disorders</td>
<td>Other psychiatric symptoms that are likely to complicate the treatment of the substance use disorder and require treatment themselves, concerns about safety in certain settings (note that assessment for co-occurring disorders should include a determination of any psychiatric medications that the patient may be taking for the condition)</td>
</tr>
</tbody>
</table>

Continued on back
<table>
<thead>
<tr>
<th>Domain</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dependent Children</td>
<td>Custody of dependent children or caring for noncustodial children and options for care of these children during rehabilitation</td>
</tr>
<tr>
<td>Trauma and Violence</td>
<td>Current domestic violence that affects the safety of the living environment, co-occurring posttraumatic stress disorder or trauma history that might complicate rehabilitation</td>
</tr>
<tr>
<td>Treatment History</td>
<td>Prior successful and unsuccessful rehabilitation experiences that might influence the decision about type of setting indicated</td>
</tr>
<tr>
<td>Cultural Background</td>
<td>Cultural identity, issues, and strengths that might influence the decision to seek culturally specific rehabilitation programs, culturally driven strengths or obstacles that might dictate level of care or setting</td>
</tr>
<tr>
<td>Strengths and Resources</td>
<td>Unique strengths and resources of the client and his or her environment</td>
</tr>
<tr>
<td>Language</td>
<td>Language or speech issues that make it difficult to communicate, or require an interpreter familiar with substance abuse</td>
</tr>
</tbody>
</table>
## Commonly Abused Inhalants

**KAP KEYS Based on TIP 45**
**Detoxification and Substance Abuse Treatment**

<table>
<thead>
<tr>
<th>Type</th>
<th>Examples</th>
<th>Chemicals in Inhalant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adhesives</td>
<td>Airplane glue</td>
<td>Toluene, ethyl acetate</td>
</tr>
<tr>
<td></td>
<td>Other glues</td>
<td>Hexane, toluene, methyl chloride, acetone, methyl ethyl ketone, methyl butyl ketone</td>
</tr>
<tr>
<td></td>
<td>Special cements</td>
<td>Trichloroethylene, tetrachloroethylene</td>
</tr>
<tr>
<td>Aerosols</td>
<td>Spray paint</td>
<td>Butane, propane (U.S.), fluorocarbons, toluene, hydrocarbons, “Texas shoe shine” (a spray containing toluene)</td>
</tr>
<tr>
<td></td>
<td>Hair spray</td>
<td>Butane, propane (U.S.), chlorofluorocarbons (CFCs)</td>
</tr>
<tr>
<td></td>
<td>Deodorant; air freshener</td>
<td>Butane, propane (U.S.), CFCs</td>
</tr>
<tr>
<td></td>
<td>Analgesic spray</td>
<td>CFCs</td>
</tr>
<tr>
<td></td>
<td>Asthma spray</td>
<td>CFCs</td>
</tr>
<tr>
<td></td>
<td>Fabric spray</td>
<td>Butane, trichloroethane</td>
</tr>
<tr>
<td></td>
<td>PC cleaner</td>
<td>Dimethyl ether, hydrofluorocarbons</td>
</tr>
<tr>
<td>Anesthetics</td>
<td>Gaseous</td>
<td>Nitrous oxide</td>
</tr>
<tr>
<td></td>
<td>Liquid</td>
<td>Halothane, enflurane</td>
</tr>
<tr>
<td></td>
<td>Local</td>
<td>Ethyl chloride</td>
</tr>
</tbody>
</table>
### Table: Chemicals in Inhalants

<table>
<thead>
<tr>
<th>Type</th>
<th>Examples</th>
<th>Chemicals in Inhalant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cleaning agents</td>
<td>Dry cleaning</td>
<td>Tetrachloroethylene, trichloroethane</td>
</tr>
<tr>
<td></td>
<td>Spot remover</td>
<td>Xylene, petroleum distillates, chlorohydrocarbons</td>
</tr>
<tr>
<td></td>
<td>Degreaser</td>
<td>Tetrachloroethylene, trichloroethane, trichloroethylene</td>
</tr>
<tr>
<td>Solvents and gases</td>
<td>Nail polish remover</td>
<td>Acetone, ethyl acetate</td>
</tr>
<tr>
<td></td>
<td>Paint remover</td>
<td>Toluene, methylene chloride, methanol, acetone, ethyl acetate</td>
</tr>
<tr>
<td></td>
<td>Paint thinner</td>
<td>Petroleum distillates, esters, acetone</td>
</tr>
<tr>
<td></td>
<td>Correction fluid and thinner</td>
<td>Trichloroethylene, trichloroethane</td>
</tr>
<tr>
<td></td>
<td>Fuel gas</td>
<td>Butane, isopropane</td>
</tr>
<tr>
<td></td>
<td>Lighter</td>
<td>Butane, isopropane</td>
</tr>
<tr>
<td></td>
<td>Fire extinguisher</td>
<td>Bromochlorodifluoromethane</td>
</tr>
<tr>
<td>Food products</td>
<td>Whipped cream</td>
<td>Nitrous oxide</td>
</tr>
<tr>
<td></td>
<td>Whippets</td>
<td>Nitrous oxide</td>
</tr>
<tr>
<td>“Room odorizers”</td>
<td>Locker Room, Rush, Poppers</td>
<td>Isoamyl, isobutyl, isopropyl or butyl nitrate (now legal), cyclohexyl</td>
</tr>
</tbody>
</table>

Management of Withdrawal From Inhalants

• It is crucial to provide the patient with an environment of safety that removes him or her from access to inhalants.
• Patients presenting with only inhalant withdrawal are unusual; clinicians should promptly ascertain if the patient has been abusing other substances and proceed with appropriate detoxification as clinically indicated.
• No systemic detoxification protocol has been established for inhalant abuse.
Ordering Information

TIP 45
Detoxification and Substance Abuse Treatment

Three Ways to Obtain Free Copies of All TIPs Products

3. You can also access TIPs online at: www.kap.samhsa.gov.

Do not reproduce or distribute this publication for a fee without specific, written authorization from the Office of Communications, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services.